• Acute idiopathic TTP (most common form)
• Congenital TTP
• HIV-associated TTP
• Pregnancy-associated TTP
• Drug-associated TTP
• Pancreatitis-associated TTP
  
  

Core Pathophysiological Mechanism

• ADAMTS13 function: This metalloprotease cleaves ultralarge vWF multimers released from endothelial cells, converting them into smaller, less thrombogenic forms.
• Deficiency effect: In the absence of sufficient ADAMTS13 activity, these multimers remain intact and abnormally bind circulating platelets.
  
  

Resulting pathology

• Formation of platelet-rich microthrombi.
• Mechanical destruction of erythrocytes (schistocyte formation).
• Consumptive thrombocytopenia and microangiopathic haemolytic anaemia (MAHA).
• End-organ ischaemia, especially in the brain and kidneys.
  
  
  

Acquired (Immune-Mediated) TTP

• Caused by inhibitory autoantibodies directed against ADAMTS13.
• These autoantibodies either neutralise enzyme function or accelerate its clearance.
  
  

• Medications:
  • Thienopyridines (e.g. clopidogrel, ticlopidine): associated with both antibody-mediated and non-immune endothelial injury variants.
  • Immunosuppressants (e.g. cyclosporine, tacrolimus): implicated via endothelial damage and possible immune dysregulation.
• Infections:
  • HIV infection is strongly associated with TTP, especially in patients with advanced disease or those not on antiretroviral therapy.
• Hormonal factors:
  • Oestrogen exposure (e.g. from combined oral contraceptives) can be a contributing factor.
• Pregnancy:
  • Particularly in the peripartum and postpartum periods; immune dysregulation and increased endothelial stress are likely mechanisms.
    
    

• More common than congenital forms.
• Frequently affects women and individuals of African descent.
  
  

Congenital TTP (Upshaw-Schulman Syndrome)

• Inherited biallelic mutations in the ADAMTS13 gene, leading to severely reduced or absent enzymatic activity.
  
  

• Patients may remain asymptomatic until exposed to a physiological stressor.
  
  

• Commonly includes:
  • Systemic infections (e.g. viral, bacterial).
  • Pregnancy: increases vWF levels and hypercoagulability.
  • Surgery or trauma: provokes endothelial activation and heightened haemostatic demand.
    
    

• Typically presents in childhood or adolescence, but can also first manifest in adulthood.
• Severe ADAMTS13 deficiency (<10%) is persistent and non-immune.
  
  

Historical and Pathological Background

• Reported terminal arteriolar hyaline thrombi in organs such as the kidneys and heart.
• These were later identified as platelet-rich, vWF-dense microthrombi.
  
  

• Accumulation of ultralarge vWF multimers on endothelial surfaces in the absence of ADAMTS13.
• Spontaneous binding of these multimers to platelets under high shear stress leads to microvascular obstruction.
  
  

• Unlike DIC, TTP thrombi do not contain fibrin or reflect consumptive coagulopathy.
  
  
  

Clinical and Therapeutic Implications

• ADAMTS13 activity <10% confirms TTP diagnosis; <5% is highly specific.
  
  

• Detection of anti-ADAMTS13 inhibitors supports acquired TTP.

• Immunosuppression (e.g. corticosteroids, rituximab) to reduce autoantibody production.
• Plasma exchange to remove autoantibodies and replenish ADAMTS13.
• Antiplatelet agents (e.g. aspirin) in selected patients to counteract vWF-platelet interactions.
  
  

Normal Physiological Role of vWF and ADAMTS13

• Serves two critical haemostatic roles:
  • Acts as a carrier for coagulation factor VIII, preventing its degradation.
  • Facilitates platelet adhesion by bridging subendothelial collagen and platelet glycoprotein receptors.
    
    

• A zinc-containing metalloprotease produced by hepatic stellate cells, endothelial cells, and megakaryocytes.
• Cleaves ultra large vWF multimers into smaller, less reactive forms.
• Prevents spontaneous platelet aggregation in areas of high shear stress (e.g. arterioles and capillaries).
  
  

Mechanism of Disease in TTP

• In >95% of acquired TTP cases, the enzyme is inhibited by circulating IgG autoantibodies.
• In congenital TTP (Upshaw-Schulman syndrome), mutations in the ADAMTS13 gene result in markedly reduced or absent enzyme activity.
  
  

• Unprocessed ultralarge vWF multimers accumulate on endothelial surfaces.
• These multimers spontaneously bind circulating platelets.
• Platelet-rich microthrombi form in arterioles and capillaries, occluding blood flow.
• Red blood cells are mechanically sheared as they pass through partially occluded vessels, forming schistocytes.
• Platelet consumption leads to thrombocytopenia.
• Tissue ischaemia follows, primarily affecting the CNS and kidneys.
  
  

Histological and Clinical Features

• Composed primarily of platelets and vWF with minimal fibrin content.
• Unlike disseminated intravascular coagulation, there is no systemic activation of coagulation or widespread fibrin deposition.
  
  

• Central nervous system: headache, confusion, seizures, and stroke-like symptoms.
• Kidneys: mild to moderate dysfunction; less severe than in haemolytic uraemic syndrome.
• Peripheral blood: presence of schistocytes, thrombocytopenia, and haemolytic anaemia.
  
  

• ADAMTS13 deficiency alone may not be sufficient to cause symptomatic TTP.
• Secondary endothelial activation (a “second hit”) appears necessary to trigger the full clinical syndrome.
  • Triggers include:
    • Infections: including Shiga toxin–producing E. coli O157 and COVID-19.
    • Pregnancy: hormonal and vascular changes contribute.
    • Autoimmune disorders.
    • Drugs: mitomycin, cyclosporine, quinine, cisplatin, ticlopidine, and alemtuzumab.
    • Malignancy and transplantation: may also contribute to endothelial dysfunction or provoke immune activation.
      
      

Unidentified TTP Variant

• A third subtype has been proposed: “unidentified TTP”.
  • Distinguished from immune TTP by:
    • Lack of anti-ADAMTS13 antibodies.
    • ADAMTS13 circulates in a "closed" conformation, not accessible to autoantibodies.
  • Clinical features differ:
    • More common in older patients.
    • Less frequent in women.
    • Often associated with malignancy.
    • Rarely accompanied by autoimmune disease.
      
      

Relation to Other Microangiopathies

• Caused by Shiga toxin-producing bacteria.
• Presents with similar clinical features (e.g. thrombocytopenia and renal injury).
• ADAMTS13 activity is usually normal, supporting a distinct pathogenic mechanism.
  
  
  

• Driven by uncontrolled complement activation.
• Shares overlapping clinical features but differentiated by complement dysregulation and normal ADAMTS13.
  
  

Incidence and Prevalence

• Global incidence of immune TTP ranges from 1.81 to 3.93 cases per million people per year.
• Prevalence is approximately 10 cases per million at any given time.
  
  

• France: 13 cases per million people per year.
• United States:
  • Estimated incidence: 4 to 11 cases per million annually.
  • Some datasets suggest up to 1 in 50,000 hospital admissions.
• United Kingdom: 2.2 cases per million annually.
• Saskatchewan, Canada: 3.2 cases per million annually.
• A combined registry analysis (TTP + HUS) in the US reported 6.5 cases per million per year.
  
  
  

Demographics and Risk Factors

• TTP affects women disproportionately, with a female-to-male ratio of approximately 2:1.
• Between 65–75% of cases in the US occur in women.
  
  

• Median age at diagnosis is typically between 39 and 52 years.
• Congenital TTP may present in childhood but is rare in the general paediatric population.
  
  

• African ancestry is associated with increased incidence; up to 44% of US patients are Black.
  
  

• A known precipitant of TTP, particularly in the peripartum period.
  
  

• Especially prevalent in sub-Saharan Africa.
• TTP occurs more frequently in HIV-positive women and in those not adherent to antiretroviral therapy.
  
  

Mortality and Morbidity

• Without treatment, TTP has a fatality rate approaching 90%.
• Introduction of plasma exchange has reduced this to approximately 10–20%.
  
  

• Thrombotic events: stroke, transient ischaemic attacks, myocardial infarction, cardiac arrhythmias.
• Renal involvement: azotaemia is frequent but typically less severe than in HUS.
• Obstetric complications: TTP in pregnancy can lead to fetal loss.
  
  

• Most survivors do not develop significant chronic sequelae.
• However, permanent neurological deficits occur in a minority.
• Relapse rates range from 13–36%, necessitating long-term monitoring.
  
  

• TTP is exceedingly rare in children.
• When it does occur, congenital TTP is more commonly represented than in adults.
• In contrast, haemolytic uraemic syndrome (HUS) accounts for the majority of thrombotic microangiopathy in paediatric patients (~90%).
  
  

Common Presenting Symptoms

• Present in ~70% of cases (most frequent)
• Major symptoms: seizures, coma, stroke-like focal deficits, transient ischaemic attacks (≈41%).
• Minor symptoms: headache, confusion, lethargy, visual disturbance, paresthesia (≈26%).
  
  

• Fatigue: common and often related to underlying haemolytic anaemia.
• Dyspnoea: frequently reported, due to anaemia or cardiac involvement.
  
  

• Occur in ~69% of patients.
• Include nausea, vomiting, diarrhoea, and abdominal pain—likely from intestinal microthrombi.
• Abdominal pain was noted as the most frequent single symptom in some studies.
  
  

• Less than 10% report spontaneous bleeding despite thrombocytopenia.
• Petechiae are common.
• Other symptoms include menorrhagia and ecchymosis (≈20%).
  
  
  

• Observed in 10–50% of cases.
• High, spiking fevers are uncommon and may suggest alternative diagnoses (e.g., sepsis).
  
  

• May be reported due to haemoglobinuria from intravascular haemolysis.
  
  

Symptom Timeline and Pattern

• Median duration from onset to diagnosis is typically within 7 days.
• The course is often subacute but can rapidly progress to life-threatening complications.
  
  

Organ-Specific Symptoms from History

• Usually mild or absent in TTP (distinguishing it from HUS).
• When present, may manifest as dark urine or non-specific malaise.

• Involvement is rare, but patients may present with shortness of breath due to anaemia or cardiac compromise.

• May present as chest discomfort or palpitations.
• Troponin elevation is associated with worse prognosis and should raise concern during initial evaluation.
  
  

High-Risk Historical Factors

• Age range typically 20–59 years; median ~40 years.
• Female predominance (65–75% of cases).
• African ancestry (up to 44% of US cases; ninefold higher relative incidence).
  
  

• TTP often occurs around the time of delivery.
• Responsible for 12–25% of diagnoses in female patients.
  
  

• BMI >30 is associated with increased risk (odds ratio 7.6).
  
  

• High-risk medications:
  • Clopidogrel (1 per 1600–5000 treated individuals), ticlopidine.
  • Mitomycin, ciclosporin, gemcitabine, tacrolimus, alemtuzumab.
  • Quinine: linked to 11% of TTP cases in a case series of 123 patients.
    
    

• HIV infection: particularly in patients not on antiretroviral therapy (odds ratio 30–35).
• Malignancy and chemotherapy: common in secondary TTP.
• Haematopoietic stem cell transplant: linked to poor response to standard therapy.
  
  
  
  

General Physical Findings

• Pallor: Reflects anaemia secondary to intravascular haemolysis.
• Jaundice: Mild scleral icterus may be present due to unconjugated hyperbilirubinaemia.
• Petechiae and ecchymoses:
  • Commonly observed on the skin, particularly in dependent areas.
  • Reflect underlying thrombocytopenia.
  • Menorrhagia may also be noted, although significant bleeding is unusual.
    
    

Neurological Signs

• Most prominent clinical domain on examination.
• Altered mental status: May range from confusion to coma.
• Focal deficits: Such as hemiparesis, aphasia, or cranial nerve palsies.
• Seizures: Can occur as part of the initial presentation or during disease progression.
• Transient ischaemic episodes: Symptoms may be fleeting and reversible, complicating diagnosis.
  
  

• Major neurological signs observed in ≈41% of patients.
• Minor neurological signs (e.g., headache, dizziness, confusion) in ≈26%.
  
  

Cardiovascular Findings

• Typically non-specific but may include:
  • Tachycardia: Due to anaemia or systemic stress.
  • Signs of myocardial ischaemia: May be silent; however, elevated troponin levels are often detected and are associated with poor prognosis.
  • Arrhythmias or heart failure signs: May be noted in severe or refractory cases.
    
    

Renal Findings

• Usually mild or absent on physical examination.
• TTP does not typically cause overt signs of renal failure at presentation.
• Proteinuria and elevated creatinine may be noted on investigations rather than clinical exam.
• Severe renal involvement is less common than in haemolytic uraemic syndrome (HUS).
  
  

Pulmonary and Abdominal Findings

• Rarely involved.
• May present with dyspnoea due to anaemia or cardiac dysfunction.
  
  

• Often benign on palpation.
• Abdominal tenderness may reflect mesenteric ischaemia secondary to microvascular thrombosis.
• Organomegaly is not characteristic.
  
  

Systemic and Constitutional Signs

• Present in a minority (~10–20%).
• When observed, tends to be low-grade.
• High spiking fevers should prompt consideration of alternate diagnoses (e.g., infection or sepsis).
  
  

• Non-specific but reported in over 60% of patients in some cohorts.
  
  

• Gastrointestinal symptoms: 69%
• General weakness: 63%
• Petechiae or purpura: 54%
• Major neurological signs: 41%
• Minor neurological symptoms: 26%
• Fever and chills: 10%
• Full classical pentad (MAHA, thrombocytopenia, neurological signs, fever, renal impairment): <5%
  
  
  
  

Essential Initial Laboratory Tests

• Platelet count: Markedly reduced in nearly all patients; <20 × 10⁹/L in ~95%.
• Haemoglobin: Mild to moderate anaemia (usually <8 g/dL); seen in ~80% of cases.
• White cell count: Often normal or mildly elevated.
  
  

• Schistocytes (fragmented red cells) indicate microangiopathic haemolysis.
• May be absent early in the disease but typically present at diagnosis.
  
  

• Reticulocyte count: Elevated due to bone marrow compensation.
• Lactate dehydrogenase (LDH): Markedly raised; levels may exceed 1000 IU/L.
• Unconjugated (indirect) bilirubin: Elevated due to breakdown of red cells.
• Haptoglobin: Significantly decreased or undetectable as it binds free haemoglobin.
• Direct Coombs’ test: Negative, ruling out autoimmune haemolytic anaemia.
  
  

• Creatinine and urea: May be mildly elevated; severe renal failure in only ~5%.
• Urinalysis: Can show proteinuria; present in ~40% of patients.
  
  

• PT/INR and aPTT: Typically normal in TTP, helping to distinguish from DIC.
• D-dimer: Normal or mildly elevated.
• Fibrinogen: High-normal to elevated; low levels suggest alternative diagnoses such as DIC.
  
  
  

PLASMIC Score

• Platelet count <30 × 10⁹/L
• Evidence of haemolysis (elevated reticulocytes, LDH, or indirect bilirubin; undetectable haptoglobin)
• MCV <90 fL
• INR <1.5
• Creatinine <176.8 μmol/L (2.0 mg/dL)
• Absence of active cancer
• No history of solid organ/stem cell transplant
• Interpretation:
  • Score ≥6: High probability of TTP
  • Score ≤4: Low probability
  • Sensitivity ≈99%, specificity ≈57%; useful as a rapid screening tool
    
    

ADAMTS13 Activity Assay

• Activity <10% in the setting of MAHA and thrombocytopenia confirms TTP.
• Some advocate <5% for greater specificity.
  
  

• Helps differentiate acquired TTP (presence of inhibitory autoantibodies) from congenital forms.
  
  

• Activity may also be reduced in conditions like sepsis, cancer, or pregnancy.
• Results are not always rapidly available, so should not delay initiation of treatment.
  
  

• Persistently low activity post-treatment predicts relapse.
• Failure to rise >10% after plasma exchange within 7 days indicates poorer outcomes.
  
  
  

Additional Investigations

• May be elevated; associated with cardiac involvement and poor prognosis.
  
  

• Recommended for all patients due to strong association with HIV, particularly in untreated cases.
  
  

• Reserved for patients with focal deficits, seizures, or altered mental status.
• Aims to exclude infarction or haemorrhage.
  
  

• Platelet-rich, fibrin-poor microthrombi.
• Most commonly affect kidneys and CNS.
• Biopsy not recommended routinely due to bleeding risk and limited diagnostic yield.
  
  
  
  

Haemolytic Uraemic Syndrome (HUS)

• More common in children.
• Preceded by diarrhoeal illness, especially due to E. coli O157:H7.
• Prominent renal dysfunction; neurological signs are less severe.

• Caused by dysregulation of the complement pathway.
• Presents with similar features to TTP.
• Recurrent episodes and lack of response to plasma exchange suggest aHUS.
• Normal ADAMTS13 activity and absence of E. coli in stool are distinguishing factors.
• Genetic testing for complement regulatory mutations may assist, although often negative in ~30–50% of cases.
  
  

Malignant Hypertension

• Severe elevation in blood pressure (e.g. systolic >200 mmHg, diastolic >130 mmHg).
• Microangiopathic haemolysis may occur.
• Thrombocytopenia resolves with control of hypertension.
• Renal and neurological abnormalities may mimic TTP, but hypertension is the primary driver.
  
  

Disseminated Intravascular Coagulation (DIC)

• Prolonged PT, aPTT, and elevated D-dimer levels.
• Associated with systemic illness (sepsis, malignancy).
• Peripheral smear shows fewer schistocytes than in TTP.
• Bleeding tendencies and organ dysfunction are typically more profound.
• Coagulation studies help differentiate from TTP (which usually has normal PT/aPTT).
  
  

• May present with thrombocytopenia and organ dysfunction.
• Signs: Fever, hypotension, altered mental state, tachycardia, and possible DIC.
• Blood cultures and inflammatory markers (CRP, procalcitonin) help confirm infection.
• Thrombocytopenia typically resolves with treatment of the underlying infection.
  
  
  

Immune Thrombocytopenic Purpura (ITP)

• Isolated thrombocytopenia.
• No haemolysis, no schistocytes, no organ dysfunction.
• Peripheral smear is otherwise normal.
• Coombs test may be positive if autoimmune haemolysis is present.
  
  

HELLP Syndrome and Pre-eclampsia

• Occur in pregnancy, especially during the third trimester.
• HELLP: Haemolysis, Elevated Liver enzymes, and Low Platelet count.
• Pre-eclampsia: New-onset hypertension with proteinuria after 20 weeks’ gestation.
• Distinguishing features:
  • Raised blood pressure and liver enzymes more typical of HELLP.
  • TTP can occur at any stage of pregnancy and does not generally involve hypertension.
    
    
    

Drug-Induced TMA

• Chemotherapeutics: Mitomycin C, gemcitabine, interferon.
• Antibiotics: Trimethoprim, penicillin, rifampin.
• Cardiovascular drugs: Clopidogrel and ticlopidine (thienopyridines).
  
  
  

• Typically occurs within the first 2 weeks of initiation.
• Frequently normal ADAMTS13 levels, suggesting endothelial injury rather than enzyme deficiency.
• Clinical features: Cutaneous signs may precede systemic involvement.
• Treatment requires plasma exchange and corticosteroids; discontinuing clopidogrel alone is insufficient.
  
  

Haematopoietic Stem Cell Transplantation-Associated TMA

• Related to:
  • Conditioning regimens (e.g., total body irradiation).
  • Calcineurin inhibitors (e.g., tacrolimus, ciclosporin).
  • Graft-versus-host disease and infections.
• Typically refractory to standard plasma exchange.
  
  

Cancer-Associated TMA

• Most commonly linked with adenocarcinomas (e.g., gastric, breast, prostate).
• Microangiopathy may be due to direct marrow invasion or release of prothrombotic factors.
• ADAMTS13 activity may be reduced but is rarely <10%.
  
  

Connective Tissue Disorders and Vasculitides

• Systemic lupus erythematosus (SLE) and antiphospholipid syndrome may mimic TTP.
• Testing:
  • Positive ANA, anti-dsDNA, antiphospholipid antibodies.
  • May coexist with true TTP or act as an independent TMA trigger.
    
    

Haemorrhagic Fevers

• Travel to endemic areas is a key historical clue.
• Manifestations include petechiae, ecchymoses, and mucosal bleeding.
• May be misinterpreted as TTP.
• Confirmed via serological testing.
  
  

Initial Management

• First-line treatment in acquired TTP.
• Removes circulating ADAMTS13 inhibitors and ultralarge vWF multimers, while replenishing functional ADAMTS13.
• Recommended to start within 24 hours of presentation.
• Protocol:
  • Initial: 1.5 plasma volume exchange daily.
  • Titrate based on clinical response (platelet count, LDH).
  • Taper gradually after 3 days of platelet and LDH stability.
• If unavailable:
  • Plasma infusion (30 mL/kg/day) may be used temporarily.
  • Transfer to a centre with PEX capability.

• Administered concurrently with PEX.
• Typically initiated as high-dose methylprednisolone or oral prednisolone.
• Helps suppress autoantibody production against ADAMTS13.
  
  

• Monoclonal nanobody targeting vWF-platelet interaction.
• Added to PEX and corticosteroids in adults with acquired TTP.
• Reduces time to platelet count normalisation and risk of relapse or thromboembolic complications.
• Continued for 30 days post-last plasma exchange.
  
  

Adjunctive Measures

• May be used cautiously once platelet count exceeds 50 × 10⁹/L.
• Long-term use to prevent microvascular thrombosis is debated.
• Should be avoided if platelets are <10 × 10⁹/L due to bleeding risk.
  
  

• Folate supplementation for haemolysis-induced deficiency.
• Red cell transfusions for symptomatic anaemia.
• Platelet transfusion only if there is active bleeding or planned invasive procedure (e.g., central line placement).
• HIV, hepatitis B/C, and pregnancy testing prior to PEX if feasible.
  
  

Monitoring and Outcome Assessment

• Baseline levels aid in diagnosis and classification.
• Post-treatment monitoring informs risk of relapse.
• Definitions:
  • Partial remission: ADAMTS13 ≥20% but <lower limit of normal (LLN).
  • Complete remission: ADAMTS13 ≥ LLN.
• Clinical remission can occur with or without biochemical remission.
  
  

• Platelet count and LDH to monitor response.
• Troponin for cardiac involvement (a poor prognostic marker).
• MRI brain if neurological symptoms persist or progress.
  
  
  

Refractory or Relapsing Disease

• Lack of platelet response after 4–7 days.
• Worsening neurological or organ dysfunction.
• Persistent low ADAMTS13 activity post-treatment.
  
  

• Rituximab:
  • Anti-CD20 monoclonal antibody.
  • Targets B cells producing anti-ADAMTS13 autoantibodies.
  • Used increasingly in the frontline setting to reduce relapse risk.
• Vincristine:
  • Alkylating agent with observed benefit in small case series.
• Cyclophosphamide:
  • Immunosuppressive; considered in refractory cases.
• Ciclosporin:
  • Calcineurin inhibitor; modest evidence of benefit.
  • Caution due to association with post-transplant TMA.
    
    

• Considered in multi-relapsing or refractory cases.
• Associated with durable remissions in some patients.
• Preoperative preparation: Pneumococcal, Haemophilus influenzae type b, and meningococcal vaccines required.
• Postoperative infection risk necessitates long-term vigilance.
  
  

Short-Term Outcomes

• Untreated TTP has a mortality rate of up to 90%.
• With prompt plasma exchange and corticosteroids, mortality decreases to 10–30%.
• Most patients respond within 10 days, and 90% will achieve response by 3 weeks of treatment initiation.
  
  

Factors Associated with Early Mortality

• Cardiac involvement:
  • Coronary thrombosis leading to myocardial infarction, heart failure, or sudden cardiac death is a recognised cause of early death.
  • Elevated troponin at presentation correlates with a significantly increased risk of mortality or treatment refractoriness.
• Neurological compromise, need for mechanical ventilation, and older age are also linked to poor early outcomes.
• Delayed treatment initiation worsens prognosis significantly.
  
  

Laboratory Predictors of Poor Prognosis

• Failure to normalise platelet counts within 7 days of starting plasma exchange.
• Persistently elevated LDH by day 5 of therapy.
• Low albumin or total serum protein levels at presentation.
• Elevated complement activation markers (e.g., Bb, sC5b-9).
• Prolonged aPTT, high fibrinogen, and raised troponin at admission are all correlated with higher mortality.
  
  

Clinical Severity Scores

• Retrospective studies have developed severity scores using parameters such as:
  • Platelet count
  • Haemoglobin level
  • Creatinine level
  • Presence of neurological symptoms
• These scores may help predict 30-day mortality, though external validation is limited.
  
  
  

Long-Term Outcomes

• Occurs in 30–36% of survivors within 10 years.
• Relapsing disease is more likely in patients with persistently low ADAMTS13 activity.
  
  

• Approximately 82% in patients without serious comorbidities.
• Drops to around 50% in those with cancer, HIV, or a history of solid organ transplantation.
  
  

Autoimmune Complications

• Individuals with a history of TTP have an increased long-term risk of developing autoimmune diseases, such as:
  • Systemic lupus erythematosus (SLE)
  • Sjögren syndrome
• This risk is especially elevated in those with anti-dsDNA or anti-SSA antibodies at the time of diagnosis.
• These findings support the recommendation for long-term monitoring for autoimmune disorders.
  
  
  
  

Disease-Related Complications

• Caused by cerebral microthrombi resulting from platelet aggregation on ultralarge vWF multimers.
• Can manifest as focal neurological deficits or seizures.
• Some neurological deficits resolve fully with treatment; others may result in permanent sequelae.
  
  

• Microvascular thrombi in renal vasculature can cause acute kidney injury (AKI).
• Renal dysfunction is typically less severe than in haemolytic uraemic syndrome.
• Usually reversible with effective TTP treatment.
  
  

• Microthrombi may involve coronary arteries.
• Studies suggest cardiac involvement occurs in up to 18% of TTP patients, potentially higher in broader thrombotic microangiopathy cohorts.
• TTP does not alter standard MI management protocols.
  
  

Complications of Plasma Exchange (PEX)

• Required in most patients for PEX.
• Risks include:
  • Infection: including bloodstream infections.
  • Mechanical complications: bleeding, pneumothorax, catheter-associated venous thrombosis.
• Reported overall complication rate: ~25%; mortality due to PEX complications: ~2–4.4%.
  
  

• Hypotension: due to rapid fluid shifts.
• Anaphylaxis: rare but serious, due to donor plasma exposure.
• Transfusion-related acute lung injury (TRALI): a potentially fatal pulmonary complication.
  
  

• Although rare, risks are present due to frequent plasma exposure:
  • HIV: ~1 in 2,100,000 units.
  • HCV: ~1 in 1,900,000.
  • HBV: ~1 in 58,000 to 1 in 269,000.
  • HTLV: ~1 in 2,000,000.
• Rigorous blood screening has significantly reduced incidence in high-resource settings.
  
  

Medication-Related Complications

• Common side effects include
  • Osteoporosis
  • Glucose intolerance
  • Hypertension
  • Immunosuppression with risk of opportunistic infections.
• Risk increases with treatment duration and cumulative dose.
  
  

• Generally well tolerated.
• Increased risk of mucocutaneous bleeding reported due to antiplatelet effects.
  
  

Other Considerations

• When plasma infusion is used as an interim measure in absence of immediate PEX access, volume overload can precipitate heart failure.
• Typically reversible once PEX is instituted.
  
  

• Studies have shown a decline in PEX-related complications over the past 15 years, likely due to improved protocols and early adjunctive therapies.

1. Amin Asnafi A, Jalali MT, Pezeshki SMS, et al. The Association Between Human Leukocyte Antigens and ITP, TTP, and HIT. J Pediatr Hematol Oncol. 2019;41(2):81–86.
2. Benhamou Y, Boelle PY, Baudin B, et al. Cardiac troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. J Thromb Haemost. 2015;13(2):293–302.
3. Bennett CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med. 2000;342(24):1773–1777.
4. Cataland SR, Jin M, Lin S, et al. The use of rituximab in patients with TTP. Blood Adv. 2017;1(15):1159–1171.
5. Coppo P, Cuker A, George JN. Thrombotic thrombocytopenic purpura: Toward targeted therapy and precision medicine. Res Pract Thromb Haemost. 2019;3(1):26–37.
6. Cuker A, Cataland SR, Coppo P, et al. Redefining outcomes in immune TTP: an international working group consensus report. Blood. 2021;137(14):1855–1861.
7. Fujimura Y, Matsumoto M. Registry of 919 patients with thrombotic microangiopathies across Japan. Intern Med. 2010;49(1):7–15.
8. George JN. How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood. 2010;116(20):4060–4069.
9. George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014;371(7):654–666.
10. Griffin D, Al-Nouri ZL, Muthurajah D, et al. First symptoms in patients with thrombotic thrombocytopenic purpura: what are they and when do they occur? Transfusion. 2013;53(1):235–237.
11. Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura. Blood. 2017;129(21):2836–2846.
12. Kojouri K, Vesely S, George JN. Quinine-associated thrombotic thrombocytopenic purpura–haemolytic uraemic syndrome: frequency, clinical features, and long-term outcomes. Ann Intern Med. 2001;135(12):1047–1051.
13. Kremer Hovinga JA, Lämmle B. Thrombotic thrombocytopenic purpura: advances in pathophysiology, diagnosis, and management. J Thromb Haemost. 2021;19(5):1181–1191.
14. Mariotte E, Veyradier A, Minkchou C, et al. Autoimmune disease risk after thrombotic thrombocytopenic purpura: findings from a French cohort. Autoimmun Rev. 2017;16(2):168–172.
15. Page EE, Kremer Hovinga JA, Terrell DR, Vesely SK, George JN. Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015. Blood Adv. 2017;1(10):590–600.
16. Pandey DK, Zakarija A, Auerbach HE, et al. Plasma exchange-related complications in patients with thrombotic thrombocytopenic purpura. Transfusion. 2005;45(8):1331–1337.
17. Peyvandi F, Scully M, Kremer Hovinga JA, et al. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2016;374(6):511–522.
18. Plautz WE, Raval JS, Dyer MR, et al. ADAMTS13: origins, applications, and prospects. Transfusion. 2018;58(10):2453–2462.
19. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med. 1991;325(6):393–397.
20. Sadler JE, Moake JL, Miyata T, et al. Recent advances in thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program. 2004:407–423.
21. Scully M, Hunt BJ, Benjamin S, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012;158(3):323–335.
22. Scully M, McDonald V, Cavenagh J, et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired TTP. Blood. 2011;118(7):1746–1753.
23. Shumak KH, Rock GA, Nair RC. Late complications of thrombotic thrombocytopenic purpura. Ann Intern Med. 1995;123(11):843–847.
24. Staley EM, Cao W, Pham HP, et al. Predictive value of biochemical markers for mortality in immune thrombotic thrombocytopenic purpura. Transfusion. 2013;53(1):70–79.
25. Swart L, Schapkaitz E, Mahlangu JN. Thrombotic thrombocytopenic purpura: A 5-year tertiary care centre experience. J Clin Apher. 2019;34(1):44–50.
26. Terrell DR, Vesely SK, Kremer Hovinga JA, Lämmle B, George JN. Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic-uremic syndromes. Am J Hematol. 2010;85(11):844–847.
27. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339(22):1585–1594.
28. van Dorland HA, Taleghani MM, Sakai K, et al. The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: key findings at enrollment until 2017. Haematologica. 2019;104(10):2107–2115.
29. Westwood JP, Thomas M, Alwan F, et al. Rituximab in the treatment of acute and relapsing thrombotic thrombocytopenic purpura. Br J Haematol. 2013;163(4):497–505.
30. Zakarija A, Kwaan HC, et al. Treatment of refractory TTP with vincristine and cyclophosphamide. Am J Hematol. 2000;65(2):150–154.
31. Zheng XL, Vesely SK, Cataland SR, et al. ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020;18(10):2496–2502.